Immunome (IMNM) AI Stock Analysis

• Market Cap: $894.82M
• Dividend Yield: N/A
• Average Volume (3M): 826.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: 16.74%
• EPS Growth: 59.89%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 87,045,006
• 10 Day Avg. Volume: 675,311
• 30 Day Avg. Volume: 826,449
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 43.32
• Enterprise Value/Gross Profit: 43.32
• Enterprise Value/Ebitda: -2.90
• 1Y Price Target: $22.38
• Price Target Upside: 117.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 52 Neutral
• Price Target: $10.00 ▼(-2.72% Downside)

Immunome's overall stock score is primarily influenced by its challenging financial performance, with significant losses impacting profitability. Despite this, there is potential for improvement due to positive revenue and cash flow growth. Technical analysis provides some positive signals, but valuation remains a concern due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Clinical Trials

Varegacestat has shown increased response rates versus nirogacestat (75% vs. 44%) in a Phase 2 trial.

Financial Position

Cash and cash equivalents are $268 million, which provides a runway into 2027.

Product Development

IMNM is also building a robust ADC pipeline, with dosing underway.

Negative Factors

Commercialization Uncertainty

The company is now pre-preparing for a commercial launch, and notes having some clarity on how to win the market without overspending on a commercial force.

Data Readout Uncertainty

The company has not guided to a timeline for a data readout from the Ph 1 trial evaluating IM-1021.

Immunome Business Overview & Revenue Model

Company Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

How the Company Makes Money

Immunome makes money primarily through the development and commercialization of its proprietary antibody-based therapeutics. The company generates revenue through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve milestone payments and royalties from the commercialization of co-developed products. Immunome may also secure funding through government grants and research funding to support its R&D efforts. Additionally, as its pipeline products advance through clinical trials and potentially reach regulatory approval, Immunome can generate significant revenues from product sales.

Immunome Financial Statement Overview

Summary

Immunome faces substantial financial difficulties, with persistent losses impacting profitability and cash flow. While the balance sheet remains robust due to strong equity, operational inefficiencies need addressing to improve financial health.

Income Statement

Immunome's income statement reflects significant challenges, with consistent net losses and negative EBIT and EBITDA margins over the periods reported. Despite some revenue growth from 2024 to TTM (Trailing-Twelve-Months), the company operates with negative profitability metrics, indicating ongoing operational difficulties.

Balance Sheet

The balance sheet shows a strong equity base with a favorable debt-to-equity ratio, suggesting financial stability. However, the company’s high cash position is offset by recurring net losses, which could pressure equity if operations do not improve.

Cash Flow

Immunome's cash flow statement highlights negative operating cash flows, though financing activities have supported liquidity. Free cash flow is persistently negative, which is concerning for long-term sustainability unless the trend reverses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.59M	9.04M	14.02M	0.00	0.00	0.00
Gross Profit	12.59M	9.04M	14.02M	-631.00K	-755.00K	-755.00K
EBITDA	-187.92M	-151.35M	-28.00M	-36.27M	-23.95M	-17.04M
Net Income	-212.39M	-292.96M	-106.81M	-37.51M	-24.71M	-17.84M
Balance Sheet
Total Assets	296.29M	240.24M	148.54M	24.05M	57.92M	44.52M
Cash, Cash Equivalents and Short-Term Investments	268.04M	217.30M	138.14M	20.32M	49.23M	39.77M
Total Debt	4.14M	4.83M	1.65M	291.00K	317.00K	613.00K
Total Liabilities	27.02M	59.08M	28.66M	7.39M	9.74M	3.18M
Stockholders Equity	269.27M	181.16M	119.88M	16.65M	48.19M	41.34M
Cash Flow
Free Cash Flow	-186.17M	-117.97M	-8.40M	-28.94M	-18.30M	-12.72M
Operating Cash Flow	-178.68M	-110.79M	-7.57M	-28.69M	-18.23M	-12.13M
Investing Cash Flow	-25.23M	-85.06M	-30.48M	-248.00K	-79.00K	-586.00K
Financing Cash Flow	182.56M	240.53M	116.41M	32.00K	27.77M	49.94M

Immunome Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 10.28 is below the 20-day moving average (MA) of 10.52, above the 50-day MA of 9.65, and above the 200-day MA of 9.75, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 53.58 is Neutral, neither overbought nor oversold. The STOCH value of 36.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	67 Neutral	$799.13M	―	-3.40%	―	22.68%	42.45%
TRVI	55 Neutral	$915.76M	―	-35.74%	―	―	-8.46%
IMNM	52 Neutral	$894.82M	―	-81.20%	―	16.74%	59.89%
PRTA	52 Neutral	$444.10M	―	-66.85%	―	-95.24%	-493.05%
DNTH	48 Neutral	$667.59M	―	-34.71%	―	17.87%	41.27%
Sector *	47 Neutral	C$212.32M	-0.23	-30.33%	3.16%	19.38%	-2.35%
KALV	45 Neutral	$643.40M	―	-121.50%	―	―	-10.46%

Immunome Corporate Events

Immunome Elects New Directors at Annual Meeting

Immunome, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders elected Isaac Barchas and Jean-Jacques Bienaimé as Class II Directors to serve until the 2028 Annual Meeting. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.